Interprotein Corporation (Japan)

As the success of therapeutic antibodies shows, PPIs are proven targets especially for cell surface receptors and growing interests are being focused on PPI modulators in the increasingly difficult R&D environment in drug discovery due to less and less druggable targets after easy targets are already harvested. Protein-protein "interactomes" predict the number of putative PPIs in the range between 130,000 to 650,000. Therefore, we are actually seeing a sea of druggable targets in front

Basic Information

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Interprotein Corporation (Japan).

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

As the success of therapeutic antibodies shows, PPIs are proven targets especially for cell surface receptors and growing interests are being focused on PPI modulators in the increasingly difficult R&D environment in drug discovery due to less and less druggable targets after easy targets are already harvested. Protein-protein "interactomes" predict the number of putative PPIs in the range between 130,000 to 650,000. Therefore, we are actually seeing a sea of druggable targets in front

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.